Lip Filler: Cost, Results, Types and How to Find a Lip Injector

Lip filler is a soft gel injected into or around the lips to create a fuller appearance.

FDA's own page calls these products dermal fillers, "also known as injectable implants, soft tissue fillers, lip and facial fillers, or wrinkle fillers," and describes them as medical device implants approved to create a smoother and/or fuller appearance in the face, including the lips.

In the US, fillers are regulated as medical device implants that FDA approves through premarket approval (PMA), and each approval names the specific areas the product may be used for.

That is what "on-label" means for a filler: a product injected into the lips is on-label there only if its own approval covers the lips, and a product used in the lips without a lip approval is being used off-label.

FDA groups filler materials into absorbable (temporary) ones — hyaluronic acid, calcium hydroxylapatite and poly-L-lactic acid — and one non-absorbable (permanent) material, PMMA microspheres in bovine collagen.

For that permanent material, FDA says it has approved only one product.

Hyaluronic acid (HA) is the material behind lines such as Juvéderm and Restylane.

FDA describes it as a sugar (polysaccharide) naturally present in skin and cartilage, and says the HA used in fillers comes from bacteria or rooster combs and is often chemically crosslinked to make it last longer in the body.

Formulation details are product-specific.

Allergan describes its Juvéderm collection as six FDA-approved hyaluronic acid fillers that all contain lidocaine, and the Restylane Kysse label describes a BDDE-crosslinked HA gel of bacterial origin at 20 mg/mL with 3 mg/mL (0.3%) lidocaine.

Age is set by FDA and by each label: FDA states fillers are approved for adults aged 22 or older (over 21), with individual product labels setting the exact age.

National figures exist, but each comes with a scope.

The American Society of Plastic Surgeons (ASPS) lists average costs of $715 for hyaluronic acid fillers, $901 for non-hyaluronic acid fillers such as Radiesse, Sculptra and Bellafill, and $743 for lip augmentation with dermal fillers.

These are average fees reported by ASPS member plastic surgeons — not med spa prices — and ASPS does not state the data year or whether the figure is per syringe or per procedure.

Allergan's consumer site says Juvéderm treatment can range from $600 to $1,400 depending on product and provider.

That is a manufacturer's range, not an average.

Because a surgeon-fee average and a maker's range measure different things, neither one is a quote.

ASPS says filler cost varies with the injector's expertise and qualifications, the type of procedure, the time and effort required and the geographic location of the office — and that health insurance does not cover dermal fillers.

Syringe sizes themselves vary by product — Revanesse Versa, Versa+ and Lips+ are approved in 1.0 mL and 1.2 mL syringes — and a "half syringe" price is a clinic pricing practice rather than a labeled product size.

Volume drives the total.

In the Restylane Kysse pivotal trial, the median volume was 0.90 mL in the upper lip and 0.80 mL in the lower lip, and Cleveland Clinic says about 1 mL is injected into the lips on average.

Two clinics charging the same rate can land on different totals if one treats with half a syringe and the other with a full one.

For a comparison of amounts, see how much lip filler you need.

One more benchmark, on demand rather than price: ASPS's 2025 statistics release did not publish procedure counts or average fees for minimally invasive treatments, but it did report that lip augmentation accounted for 23% of hyaluronic acid filler treatments.

Manufacturer rewards programs can offset part of the cost.

Allergan's Allē program gives 100 points = $10 toward qualifying treatments including Juvéderm, and Galderma's ASPIRE program (Restylane and other Galderma products) offers a $20-off welcome reward, 100 points = $10 and up to 600 points per visit.

Program terms change, so check them before you book.

The honest answer is a range, and the source of the figure matters.

FDA's material-level estimate is that hyaluronic acid filler effects last approximately 6 to 12 months — a general figure for the material, not a lip-specific promise.

The makers of the lip products give their own figures.

Allergan says results from Juvéderm Volbella XC and Juvéderm Ultra XC in the lips can last up to 1 year with optimal treatment — a manufacturer claim, not a guarantee or an average.

Teoxane and Revance say their RHA fillers last up to 15 months in dynamic wrinkles and folds and up to a year in cheeks, lips and lipstick lines.

The most lip-specific trial figure comes from the Restylane Kysse US pivotal trial: 60% of treated subjects (101 of 169) were still lip-fullness responders — at least a 1-point improvement on a blinded evaluator's lip fullness scale — at week 48, roughly a year after treatment.

Two more caveats belong here.

First, biodegradation varies by individual and treatment area, and the Kysse label notes that product remnants may remain in tissue even after the visible effect has returned to baseline.

Second, visible effect is not the same as physical presence: an MRI study of 33 patients found mid-face HA filler still detectable in all of them at least 2 years after injection, with some filler visible 8 to 15 years later.

Which filler is "best" is not written in any approval: each product's approval covers its own areas and wording, so what follows compares what the approvals say — not which product is best.

What you can check is whether a product is actually approved for the lips.

Based on FDA's premarket approval (PMA) records current through 2026-10-12, the products with lip-augmentation approvals include:

• Restylane — approved for lip augmentation on 2011-10-11, the first US filler with a lip indication; Restylane-L (with lidocaine) followed on 2012-08-30
• Restylane Silk — approved 2014-06-13 for lip augmentation and correction of perioral lines in patients over 21
• Juvéderm Ultra XC — approved 2015-09-30 for injection into the lips and perioral area for lip augmentation in adults over 21
• Juvéderm Volbella XC — approved 2016-05-31 for lip augmentation and correction of perioral lines in adults over 21
• Restylane Kysse — approved 2020-03-26 for lip augmentation and correction of upper perioral lines in patients over 21
• Revanesse Lips+ — approved 2020-09-21 for lip augmentation in patients 22 or older
• RHA 3 — approved 2023-10-27 for the vermilion body, vermilion border and oral commissures for lip augmentation and lip fullness in adults 22 or older; it is the only RHA product with a lip indication
• Belotero Intense (+) Lidocaine — approved 2026-07-09 for lip augmentation in adults over 21

Two mix-ups are worth naming.

Revanesse Versa is approved only for moderate to severe facial wrinkles and folds such as nasolabial folds — not lips; the Prollenium product approved for lips is Lips+, so "Versa for lips" is off-label — a use the product's approval does not cover.

Juvéderm Ultra Plus XC is approved only for wrinkles and folds too — unlike Ultra XC, it has no lip indication — and among Teoxane's RHA line, RHA 2 is not approved for lips; only RHA 3 is.

So which is best for you?

That is a question for a licensed injector who can examine your lips and explain which FDA-approved product fits your case — this guide does not rank products or recommend one.

What the approvals do show is where the lip products differ: whether the indication covers lips only, lips plus the perioral area, or lips plus perioral lines, whether the age minimum is over 21 or 22-plus, and how each is formulated (Kysse, for example, is a 20 mg/mL HA gel with 0.3% lidocaine).

For how filler compares with a lip flip, see lip flip vs filler.

The products are injected with a needle or a cannula, according to Allergan, which also says Juvéderm results are visible immediately after treatment.

Lidocaine is named in the labeling for Juvéderm and Restylane Kysse: Allergan says all six of its fillers contain it, and the Restylane Kysse label lists 3 mg/mL (0.3%).

For a walkthrough of the appointment, see the lip filler process.

What patients actually reported gives a better picture than marketing does.

In the Restylane Kysse trial's diary data, the most common lip reactions after initial treatment were swelling (90.2%), tenderness (87.4%) and bruising (85.8%), and most were tolerable and lasted less than 2 weeks.

Counting formally recorded adverse events, treatment-related events occurred in 21.1% of Kysse subjects, most often injection-site mass (10.3%), bruising (7.6%) and nodules (5.4%); masses and nodules typically lasted under 30 days and bruising under 14 days.

For what to expect as swelling settles, see lip filler swelling stages.

On timing, Cleveland Clinic says lip filler swelling usually goes away after 24 to 48 hours but may take up to a week, that injection pain should fade after 12 to 24 hours, and that a follow-up visit is typically scheduled about two weeks later to review the final result.

The Kysse label expects injection-related reactions — bruising, redness, itching, swelling, pain and tenderness — to generally resolve on their own within one week.

Allergan says side effects with Volbella XC in the lips were mild or moderate and generally lasted 30 days or less.

How much product is used shapes both the look and the price.

In the Kysse trial, the median total volume for initial plus touch-up treatment was 2.50 mL across all areas, including a median 0.90 mL in the upper lip and 0.80 mL in the lower lip, with a median 1.30 mL at retreatment.

Cleveland Clinic says about 1 mL is injected into the lips on average, and the Kysse label sets a recommended maximum of 6 mL per patient per treatment — 3 mL for the lips and 3 mL for the perioral area.

One more warning from the Kysse label: filler injection may reactivate herpes (cold sores) in people with a history of herpetic eruptions — worth telling your provider about before treatment if cold sores are something you get.

Start with the full list FDA gives.

Common filler risks are bruising, redness, swelling, pain, tenderness, itching and rash; less common risks include nodules or granulomas, infection, allergic reaction and necrosis; rare reported risks include anaphylaxis, migration of filler, permanent hard nodules, blindness, stroke and death.

FDA also notes that most swelling and bruising appear soon after injection and many resolve in days to weeks, but some side effects may appear weeks, months or years later.

Allergan's important safety information for Juvéderm names the most common side effects as redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration and itching, and says most resolve within 30 days.

Lips are a site where the serious risk deserves plain language.

The Restylane Kysse label warns that injection into vessels can cause embolization, occlusion, ischemia or infarction, and that localized superficial necrosis and scarring may occur after injection in or near vessels, "such as in the lips."

How often does a vascular occlusion happen?

In a 2021 JAMA Dermatology study of 370 US board-certified dermatologists reporting 1.7 million filler syringes, vascular occlusion occurred about once per 6,410 one-milliliter syringes injected with needles and once per 40,882 with cannulas; risk never exceeded 1 per 5,000 syringes for any filler type, 85% of occlusions had no long-term sequelae, and nasolabial folds and lips were the sites most likely to be occluded.

These are self-reports from experienced dermatologists, not a measure of every injector.

A 2023 review of 53 published lip-filler complication cases found nodules were the most common complication, with migration, discoloration and herpes outbreaks also linked to lip filler placement.

Delayed-onset nodules after Allergan's Vycross fillers (Volbella, Vollure, Voluma) occurred in 0.33% of 2,139 patients at one Canadian clinic and at 1.0% per patient for Volbella in an earlier US chart review — and every nodule in the US series resolved with steroid injection plus hyaluronidase.

For how it is spotted and corrected, see lip filler migration.

Cleveland Clinic’s lip filler risk list includes migration: filler may move into other areas of the face, usually toward the nose.

A 2026 ultrasound study of 126 people found the lip's subcutaneous layer averages under 1 millimeter, so HA lip filler often ends up inside the lip muscle; vertical injection techniques were associated with deeper deposition, hypervascularity and evidence of migration.

Post-marketing reports for Restylane Kysse add context on serious events: the most commonly reported (three or more reports) were ischemia/necrosis, swelling, angioedema, infection and nodules.

These are spontaneous reports, not incidence rates.

Who should be cautious?

FDA says filler safety is unknown during pregnancy and breastfeeding, in people under 22, and in people prone to keloid or hypertrophic scarring, and that treatment should be delayed if the skin is inflamed or infected.

FDA also says to tell the provider about bleeding disorders, severe allergies or anaphylaxis, and allergies to lidocaine, collagen, eggs, animal products or bacteria.

Juvéderm is specifically contraindicated with a history of multiple severe allergies or anaphylaxis, allergy to lidocaine or to the gram-positive bacterial proteins used in the products, or prior allergic reactions to HA fillers.

The Kysse label adds that people with darker skin (Fitzpatrick types IV–VI) or abnormal wound healing may be more prone to hypertrophic scarring and keloids, and that inflammatory pigment changes and scarring may occur.

Two evidence gaps are worth knowing: FDA notes that the safety of fillers combined with neuromodulators such as Botox, and of repeated use over a long period, has not been evaluated in controlled clinical studies.

What about reversing a result you do not like?

Hyaluronidase breaks down hyaluronic acid fillers only.

Cleveland Clinic says dissolving usually takes one to two visits with full results in up to two weeks, and that providers ask about bee-sting allergy before using it.

Dissolving filler is off-label: hyaluronidase products such as Hylenex are FDA-approved only to aid subcutaneous fluid administration, to increase the dispersion and absorption of other injected drugs, and in subcutaneous urography.

FDA adds that removing filler can require injections, surgery or other interventions and may be difficult or impossible, especially for fillers not made of HA — and Allergan says the effectiveness of removal of any dermal filler has not been studied.

When a vascular occlusion does happen, expert reviews list prompt recognition and immediate hyaluronidase as the mainstay of treating HA-filler occlusion, and recommend emergency preparedness — a "filler crash cart" and an in-office action protocol with agents readily available.

FDA's advice is concrete: choose a licensed health care provider with dermatology or plastic-surgery experience who is trained in filler injection, and treat filler as a medical procedure, not a cosmetic treatment.

Who may legally inject — and under what supervision — is decided under rules that vary by state.

AmSpa, the American Med Spa Association, gives a general description of the common delegation model that has RNs — and in some states LPNs/LVNs or medical assistants — performing treatment with injectable toxins and dermal fillers with documented training, pursuant to a patient exam and treatment order.

That is a trade association’s general picture, not each state’s law, so it is worth checking your state’s medical or nursing board rules before you book.

Experience is measurable, and it shows up in the complication data.

In the same JAMA Dermatology survey of 370 dermatologists, injectors with more than 5 years of experience had lower odds of reporting a vascular occlusion than less experienced injectors — self-reported data, but a concrete reason to ask how long someone has been injecting filler.

FDA also expects injectors to be ready for the rare emergency.

It tells injectors to know the signs of intravascular injection, to have an updated plan detailing how a patient would be treated if it happens, and to stop injecting at signs such as skin blanching, vision change, stroke signs or unusual pain.

Expert reviews go further, recommending emergency preparedness with a "filler crash cart" and treatment agents readily available in the office.

Red flags close the loop.

FDA says needle-free devices are not approved for injecting dermal fillers, that no filler is approved for over-the-counter use, and that people should not inject themselves or buy filler online.

FDA has also warned that unapproved versions of Juvéderm (Juvederm Ultra 2, 3 and 4) have been sold in the US, including online, and should not be used.

Prices, products and injector qualifications vary clinic by clinic and city by city, so the useful comparison work is local.

Before you book anywhere, it helps to have three things in writing: which product would be used and whether it carries a lip approval, the per-syringe or per-treatment price including any touch-up, and who exactly will perform the injection and what training they have.

Timing is the other local decision.

Cleveland Clinic suggests booking lip filler at least two weeks before a big event, which fits the recovery window in the trial data — most injection-site reactions in the Kysse trial lasted less than 2 weeks.

Keep FDA's framing in mind as you compare: having filler injected should be considered a medical procedure, not a cosmetic treatment.

A provider who measures, names the exact product and its approval, quotes the full price and can describe their emergency plan is showing you exactly what that framing points to.